MIST Milestone Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 23 March 2020 Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment

   – Study missed primary endpoint of mean time to conversion of SVT to SR over a five-hour period following dosing (p=0.12) – – Etripamil showed rapid conversion of SVT to SR during the first 45 minutes (p=0.02),

2. 06 March 2020 Milestone Pharmaceuticals Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Clinical and Corporate Update

   – Topline data from Phase 3 NODE-301 trial of etripamil in patients with PSVT expected this month –  MONTREAL and CHARLOTTE, N.C., March 6, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a

3. 27 November 2019 Canadian VC at $5.1B at 3Qs 2019, with historical record $6.5B within reach

   TORONTO, Nov. 27, 2019 /CNW/ - Canadian venture capital (VC) disbursements are continuing red-hot record-setting pace, completing 452 financings totalled $5.1billion (excluding Verafin deal1) in the first three quarters

4. 14 November 2019 Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

   MONTREAL and CHARLOTTE, N.C., Nov. 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced that Joseph G. Oliveto, President and Chief Executive Officer, will present at the following

5. 13 November 2019 Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update

   – NODE-301 topline data readout expected in mid-1H20 – – Richard Pasternak, M.D. appointed to the Company's Board of Directors – MONTREAL and CHARLOTTE, N.C., Nov. 13, 2019 /PRNewswire/ -- Milestone Pharmaceuticals

6. 03 October 2019 Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT

   MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment

7. 03 October 2019 Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT

   MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the

8. 10 September 2019 Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development

   MONTREAL and CHARLOTTE, N.C., Sept. 10, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the

9. 10 September 2019 Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development

   MONTREAL and CHARLOTTE, N.C., Sept. 10, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the